ストックスクリーナーアプリを入手
2.38
3.03%
0.07
Cabaletta Bio Inc (CABA) 最新ニュース
Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities By Investing.com - Investing.com South Africa
Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities - Investing.com
Cabaletta Bio (NASDAQ:CABA) Lowered to "Inline" Rating by Evercore ISI - MarketBeat
Wells Fargo Downgrades Cabaletta Bio (CABA) - MSN
Charles Schwab Investment Management Inc. Raises Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
Cabaletta Bio (NASDAQ:CABA) Downgraded by Wells Fargo & Company to Equal Weight - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces pivotal moment - Investing.com
Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? - Simply Wall St
Point72 Asset Management L.P. Makes New $3.15 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Jennison Associates LLC Reduces Stake in Cabaletta Bio Inc - GuruFocus.com
PRUDENTIAL FINANCIAL INC's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
Walleye Capital LLC Acquires 212,025 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MSN
Weekly Analysts’ Ratings Updates for Cabaletta Bio (CABA) - Defense World
Unusually active option classes on open December 2nd - TipRanks
Cabaletta Bio (NASDAQ:CABA) Raised to Strong-Buy at TD Cowen - Defense World
Cabaletta Bio Sees Unusually High Options Volume (NASDAQ:CABA) - MarketBeat
US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode - Benzinga
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives $27.30 Consensus PT from Analysts - MarketBeat
Caballeta Bio Shares Surge The Most In 23 Months In A Single Day As It Unveils Plan To Meet FDA By 2025 For Systemic Sclerosis Drug Trial - Benzinga
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 - MSN
Cabaletta Bio’s CAR-T CABA-201 Effects Clinical Responses in Autoimmune Diseases - CGTLive™
Cabaletta Bio to Participate in Upcoming Investor Conferences in December - The Manila Times
2 Penny Stocks That Wall Street Predicts Will Soar 306% To 1,183% In 2025 - Barchart
2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025 - Inkl
Cabaletta Bio Inc (CABA-Q) QuotePress Release - The Globe and Mail
Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 - MSN
Cabaletta Bio, Inc. Set to Engage at Key Investor Conferences - MSN
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN
Cabaletta Bio shares retain Buy rating as H.C. Wainwright sees robust treatment effect - Investing.com
Cabaletta reports promising autoimmune therapy results By Investing.com - Investing.com Australia
Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times
Cabaletta reports promising autoimmune therapy results - Investing.com
Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright - Defense World
Inflammatory Myositis Treatment Market: Segmentation Trends, - openPR
Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat
Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK
Cabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Cabaletta Bio price target lowered to $12 from $20 at Wells Fargo - TipRanks
Cabaletta Bio Inc. (CABA) Quarterly 10-Q Report - Quartzy
T. Rowe Price Investment Management, Inc. Reduces Stake in Cabal - GuruFocus.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target - Investing.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target By Investing.com - Investing.com UK
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):